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Bifidogenic effect and stimulation of short chain fatty acid (SCFA) production by fractions of
oligosaccharides with a DPo3 and Gal b(1-6) linkages synthesised from lactose or lactulose by
Pectinex Ultra SP-L and Lactozym 3000 L HP G were evaluated in human faecal slurries. Results
were compared with those obtained for the commercial oligosaccharide mixture Vivinal-GOS.
Quantitative real-time PCR showed that all galacto-oligosaccharide (GOS) fractions stimulated
slightly higher bifidobacteria growth than lactose, lactulose and Vivinal-GOS. GOS fractions
promoted the production of total SCFA and acetic acid in a similar way to Vivinal-GOS and
more than glucose, lactose and lactulose. In conclusion, oligosaccharides derived from lactose
and lactulose may represent a suitable alternative to lactulose for the design of new functional
food ingredients.
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There is an increasing awareness of the importance of
human intestinal microbiota in maintaining host health.
Although little is known about all groups of bacteria in-
volved in these beneficial properties, it is generally ac-
cepted that bifidobacteria and lactobacilli play a key role
in this process (Tuohy et al. 2005).
Growth and metabolic activity of bifidobacteria can be
selectively stimulated by non-digestible oligosaccharides
considered as prebiotics (Gibson & Roberfroid, 1995). At
the same time prebiotics are able to reduce the popu-
lations of non-beneficial bacteria by favouring microbial
competition (Chow, 2002). Short chain fatty acids (SCFA;
acetate, propionate or butyrate) are the main end products
arising from microbial fermentation of these carbohydrates
and they are recognised to exert health benefits on the host
(Cummings, 1981; Topping & Clifton, 2001; Macfarlane
& Macfarlane, 2003). Enhanced SCFA production and in-
creased delivery of these compounds in the distal colon,
especially butyrate, may have a role in preventing colon
cancer and other intestinal disorders (Wong et al. 2006).
Fermentation reactions in the colon are dependent on
several factors related to the gut environment such as pH
(Louis et al. 2007) and chemical composition of the
available substrates (Wong et al. 2006). Thus, the relative
resistance of oligosaccharides to microbial degradation
mainly depends on the type of monosaccharide moieties,
glycosidic linkages, and degree of polymerisation (DP)
(Delzenne, 2003; Dongowski et al. 2005). In general,
rapidly fermented oligosaccharides would show bifido-
genic effects mainly in the caecum and proximal colon,
whereas those more resistant would be able to modify the
composition of the microbiota in the distal colon. Taking
into account the complexity of the intestinal microbiota
and that different areas of the colon may be affected by
diseases, no single oligosaccharide preparation may be
suitable for all applications or individuals (Holt et al.
2005).
Galactooligosaccharides (GOS) and lactulose are rec-
ognised as prebiotic carbohydrates and they are widely
used in Europe, Japan and the United States (Tuohy et al.
2005). GOS are usually produced by enzymatic trans-
galactosylation of lactose (Mahoney, 1998; Panesar et al.
2006). Several commercial products containing GOS are
currently available in the market, and they usually contain
a mixture of tetrasaccharides, trisaccharides, lactose, glu-
cose, and galactose (Shin & Yang, 1998; Hsu et al. 2007).
Lactulose, a synthetic disaccharide manufactured by
isomerization of lactose in basic media, was the first*For correspondence; e-mail : mvillamiel@ifi.csic.es
Journal of Dairy Research (2009) 76 317–325. f Proprietors of Journal of Dairy Research 2009 317
doi:10.1017/S0022029909004063 Printed in the United Kingdom
carbohydrate commercialised with recognised beneficial
effects on gut bifidobacteria (Mendez & Olano, 1979;
Rycroft et al. 2001; Aider & Halleux, 2007). However, its
use can be limited since it is fermented in the proximal
colon, which results in gas production (Cristl et al. 1992;
Tuohy et al. 2005).
The understanding of structure-function relationships of
prebiotics is directing the research towards specific struc-
tures with a higher level of functionality. In general, scarce
information is currently available about the structure-
function relationships of these molecules (Barreteau et al.
2006). Recently, our research group has obtained mixtures
of GOS derived from lactose and lactulose using com-
mercial enzymatic preparations (Cardelle-Cobas et al.
2008a, b; Martı´nez-Villaluenga et al. 2008a, b). However,
neither the bifidogenic effect of these oligosaccharides nor
the production of compounds due to the metabolism of
bifidobacteria has been tested. This information could be
of great interest in order to broaden the range of com-
pounds with improved functionality on the gut microbiota.
In the present work, the stimulation of the bifidobacteria
growth and metabolic activity of intestinal microbiota by
oligosaccharides (DPo3) derived from the reaction of lac-
tose or lactulose with Pectinex-Ultra SP-L and Lactozym
3000 L HP G has been investigated in vitro by using human
faecal slurry cultures.
Materials and Methods
Reagents
Lactose monohydrate and lactulose (>98% purity) were
supplied by Scharlau Chemie S.A. (Barcelona, Spain) and
Fluka (Steinheim, Germany), respectively. Soluble enzy-
matic preparations of b-galactosidase from Aspergillus
aculeatus (Pectinex Ultra SP-L) and Kluyveromyces lactis
(Lactozym 3000 L HP G) were kindly provided by
Novozymes A/S (Dittingen, Switzerland and Bagsvaerd,
Denmark). Commercial product ‘Vivinal-GOS’ was a gift
from Friesland Food Domo (Hanzeplein, The Netherlands),
and contains approximately 45% GOS and 30% digestible
sugars: lactose (15%), glucose (14%), and galactose (1%)
(Anthony et al. 2006). Bio-Gel P-2 fine grade with bead
size <45 mm and molecular weight (MW) fractionation
range 100–1,800 Da was purchased from Bio-Rad labora-
tories (Hemel Hempstead, Hertfordshire, U.K.).
Enzymatic synthesis and purification of oligosaccharides
derived from lactose and lactulose
The enzymatic syntheses of GOS were carried out to
obtain the highest yield of oligosaccharides with DP o3.
Four batches involving the combination of two substrates
(lactose and lactulose) and two enzyme sources (Pectinex
Ultra SP-L and Lactozym 3000 L HP G) were used as
follows.
GOS-1 (Lactose-Lactozym derived oligosaccharides). A
lactose solution of 250 g/l was prepared in 0.05 M potass-
ium phosphate buffer containing 1 mM MgCl2 pH 7.5 and
b-galactosidase from Lactozym 3000 L HP G was added
at a final concentration of 3 U/mL. Reaction was per-
formed at 40 8C in an orbital shaker at 300 rpm for 2 h
(Martı´nez-Villaluenga et al. 2008a).
GOS-2 (Lactose-Pectinex derived oligosaccharides). Sol-
utions of lactose (300 g/L) were prepared in 0.1 M-sodium
phosphate buffer pH 6.5. b-galactosidase from Pectinex
Ultra SP-L was added to a final concentration of 16 U/ml.
Reactions were performed at 60 8C in an orbital shaker at
300 rpm for 7 h (Cardelle-Cobas et al. 2008a).
GOS-3 (Lactulose-Lactozym derived oligosaccharides). A
lactulose solution of 250 g/l was prepared in 0.05 M-
potassium phosphate buffer containing 1 mM-MgCl2 pH 6.5
and b-galactosidase from Lactozym 3000 L HP G was ad-
ded at a final concentration of 6 U/ml. Reaction was per-
formed at 50 8C in an orbital shaker at 300 rpm for 2 h
(Martı´nez-Villaluenga et al. 2008b).
GOS-4 (Lactulose-Pectinex derived oligosaccharides).
Solutions of lactulose (450 g/l) were prepared in 0.1 M-
sodium phosphate buffer pH 6.5. b-galactosidase from
Pectinex Ultra SP-L was added to a final concentration of
16 U/ml. Reactions were performed at 60 8C in an orbital
shaker at 300 rpm for 7 h (Cardelle-Cobas et al. 2008b).
Inactivation of enzymes was performed by immersion of
reaction mixtures in boiling water for 5 min. Mono- and
disaccharides from the reaction mixtures as well as from
the commercial Vivinal-GOS were removed using gel
permeation chromatography. In brief, fractionation was
performed in a column (100r2.5 cm) of Bio-Gel P-2
(bead size <45 mm) at 5 8C. Bidistilled water was used as
eluent at a flow rate of 15 ml/h. Fractions of 5 ml were
collected in a fraction collector and the elution of car-
bohydrates was monitored by high-performance anion-
exchange chromatography with pulsed amperometric
detection (HPAEC-PAD) as described later. Fractions of
purified GOS containing a DPo3 were pooled and freeze-
dried for in vitro fermentation assays with human faecal
slurries.
Analysis of oligosaccharides by HPAEC-PAD
GOS fractions were characterized by HPAEC-PAD on
ICS2500 Dionex system consisting of GP50 gradient pump,
and ED50 electrochemical detector with a gold working
electrode and Ag/AgCl reference electrode. Data acqui-
sition and processing was performed with Chromeleon
version 6.7 software (Dionex Corp., Sunnyvale, CA). For
eluents preparation, MilliQ water (Millipore Ibe´rica, S.A.U.,
Madrid, Spain), 50% (w/v) NaOH (Fluka, Germany) and
318 A Cardelle-Cobas and others
NaOAc (Fluka, Germany) were used. All eluents were
degassed by flushing with He for 25 min. Separations were
performed following the method described by Splechtna
et al. (2006). Elution was at room temperature on a
CarboPac PA-1 column (250r4 mm) connected to a
CarboPac PA-1 (50r4 mm) guard column. Eluent A
(100 mM-NaOH), eluent B (100 mM-NaOH and 50 mM-
NaOAc) and eluent C (100 mM-NaOH and 1 M-NaOAc)
were mixed to form the following gradient : 100% A from
0 to 20 min and 0 to 100% B from 20 to 70 min. After
each run, the column was washed for 10 min with 100%
eluent C and re-equilibrated for 15 min with the starting
conditions of the gradient used. Separations were performed
at a flow rate of 1 ml/min. Detection time and voltage
parameters were set as follows: E1=0.1 V (t1=400 ms),
E2= –2.0 V (t2=10 ms), E3=0.6 V, E4= –0.1 V (t4=60 ms);
tt=500 ms. Samples and standard solutions were filtered
through a 0.45 mm nylon filter (Symta, Spain), 25 ml were
injected using an autosampler and separations were per-
formed at a rate of 1 ml/min. Quantification of oligo-
saccharides (DPo3) was performed by external calibration
using raffinose (Sigma, St. Louis, MO) as standard.
Faecal batch culture fermentations
Three independent trials, each corresponding to faecal
batch fermentations made in independent duplicate
experiments by using samples of three different donors,
were carried out in the carbohydrate-free basal medium
(CFBM) described by Al-Tamimi et al. (2005). In each
batch, CFBM was distributed into 8 glass tubes (2.5 ml per
tube) containing each 15 mg of different carbon sources:
GOS mixtures derived from lactose and lactulose by dif-
ferent enzymatic reactions (GOS-1 to GOS-4) as well as
Vivinal-GOS, and the reference sugars lactulose, lactose
and glucose. One additional tube was kept without carbon
source added and was used as a control. After complete
dissolution, carbon sources were sterilized by filtration
through a 0.45 mm membrane. Before use, the tubes were
maintained overnight at 37 8C in anaerobiosis.
The faecal slurry inocula were prepared as follows:
faeces from three healthy adult volunteers (two female and
one male, 30–40 years old), who had not received anti-
biotics during the previous 6 months and had no history of
gastrointestinal disorder, were separately diluted in sterile
0.17 M-phosphate buffered saline (PBS) pH 7.3 to 10% w/v
and homogenised with a Lab-Blender 400 stomacher
(Seward Medical, London, UK) for 2 min. The faecal
homogenates of each donor (10 ml) were poured into
90 ml CFBM and allowed to stabilize by keeping at 378
overnight C under anaerobic conditions.
Control and tubes containing the different carbohy-
drates were mixed with 2.5 ml stabilised faecal slurry, so
that the final concentration of each carbohydrate was
0.3%. Fermentations were carried out at 37 8C under an-
aerobic conditions (10% v/v H2, 10% CO2, and 80% N2)
in a chamber Mac 500 (Don Whitley Scientific, West
Yorkshire, UK). Samples were taken at 0, 8 and 24 h of
incubation. One ml of cultures were centrifuged (12 000 g,
10 min) at each time and pellets and supernatants were
collected for analyses.
Analysis of bifidobacteria in faecal cultures by
quantitative real-time PCR
The quantification of the Bifidobacterium population in
faecal batch fermentations was performed by quantitative
real-time PCR using previously described genus-specific
primers (Gueimonde et al. 2004). DNA isolation was per-
formed with the QIAamp DNA stool Mini kit (Qiagen,
GmbH, Hilden, Germany) according to the instructions of
the manufacturer.
All reactions were performed on MicroAmp optical
plates sealed with MicroAmp optical caps (Applied
Biosystems, Foster City, CA) and amplifications were car-
ried out in a 7500 Fast Real Time PCR System (Applied
Biosystems) using the SYBR Green PCR Master Mix
(Applied Biosystems). One ml purified DNA was used as
template in the 25 ml PCR reaction. Thermal cycling con-
sisted of an initial cycle of 95 8C 10 min followed by
40 cycles of 95 8C 15 s and 60 8C 1 min. Standard curves
were made with the strain Bifidobacterium longum
NCIMB8809 which was grown overnight in MRSC (MRS
broth, Difco, Becton, Dickinson & Co, France, Supplemen-
ted with 0.25% Cysteine-HCL, Sigma) under anaerobic
conditions. Standard curves were obtained by plotting
the cycle threshold (Ct) values obtained for the standard
culture as a linear function of the base-10 logarithm of the
initial number of cells in the culture determined by plate
counting. The numbers of Bifidobacterium cells in faecal
samples was determined by comparing the Ct values ob-
tained with the standard curve. Samples were analysed in
duplicate in at least two independent PCR runs for each
faecal slurry trial.
Analysis of SCFA in faecal batch cultures by GC
The SCFA were quantified in supernatants of faecal cul-
tures by GC-FID. Cell-free supernatants from faecal cul-
tures were filtered through 0.2 mm membranes and mixed
with 1/10 ethyl-butyric acid (2 mg/ml) as internal standard
(IS) for checking reproducibility and for quantification.
Samples were immediately analysed using a GC 6890N
with a FID detector (Agilent Technologies Inc., Palo Alto,
CA) coupled with an automatic injector 7683B Series
(Agilent). Data were collected with the Agilent Chemstation
software. Samples (1 ml) were injected in the GC equipped
with an HP-FFAP capillary column (25 mr0.32 mm in-
ternal diameter, with a 0.52 mm film thickness; Agilent)
using He as gas carrier with a constant pressure of 8 psi.
The temperature of the injector was kept at 220 8C and the
split ratio was 30 : 1. Chromatographic conditions were
130 8C, 5 deg C/min up to 180 8C and then 20 deg C/min
up to 220 8C for column cleaning. The temperature of FID
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detector was kept at 250 8C. The concentration (ng/ml) of
each SCFA was calculated using the linear regression
equations (R2o0.99) from the corresponding curves of
standards obtained with six different concentrations. Stan-
dards employed were acetic, propionic, isobutyric, butyric,
isovaleric, valeric and caproic acids (Sigma Chemical Co.,
St. Louis, MO). Additionally, some samples were analysed
by GC-MS to confirm their mass spectra in a GC 6890N
coupled to a mass spectrometer 5973N detector (Agilent)
employing the Enhanced ChemStation G1701DA software
and the HP-Wiley 138 library.
Results and Discussion
Chemical composition of oligosaccharide fractions
derived from lactose and lactulose
During the enzymatic hydrolysis of lactose and lactulose
with Pectinex Ultra SP-L and Lactozym 3000 L HP G,
complex mixtures of disaccharides and trisaccharides with
linkages b(1-6), b(1-4), and b(1-3) are produced by trans-
galactosylation, trisaccharides being the main reaction
products. However, considerable concentrations of mono-
saccharides as well as lactose, lactulose and other di-
saccharides remain in the reaction mixtures (Macfarlane
et al. 2006; Cardelle-Cobas et al. 2008a, b; Martı´nez-
Villaluenga et al. 2008a, b). In order to obtain GOS-
enriched fractions, a purification step is needed. Figure 1
illustrates the chromatographic profiles obtained by
HPAEC-PAD analysis for the purified oligosaccharide
fractions derived from lactose (A) and lactulose (B) with
Pectinex Ultra SP-L or Lactozym 3000L HP G and, more-
over, the commercial mixture Vivinal-GOS (C) after
purification as well. After purification, GOS-1 (Lactose-
Lactozym derived oligosaccharides) fraction was enriched
in 6k galactosyl lactose (peak 1) being the major com-
pound found (81%). GOS-2 (Lactose-Pectinex derived
oligosaccharides) fraction consisted of 42% 6k galactosyl
lactose (peak 1), 8% 4k galactosyl lactose (peak 4) and
50% other oligosaccharides (OOS) with higher retention
times. GOS-3 (Lactulose-Lactozym oligosaccharides) frac-
tion was characterized mainly by the presence of two
trisaccharides, 6k galactosyl lactulose (peak 2) and b-D-
Gal–(1p4)-b-D-Fru-(1p1)-b-D-Gal (peak 3) in a percent-
age of 36% and 47%, respectively. GOS-4 (Lactulose-
Pectinex derived oligosaccharides) fraction exhibited 47%
of 6k galactosyl lactulose (peak 2), 6% of b-D-Gal–(1p4)-
b-D-Fru-(1p1)-b-D-Gal (peak 3) and 47% OOS with
higher retention time. These compounds were identified by
NMR (Martı´nez-Villaluenga et al. 2008b; Cardelle-Cobas
et al. 2008b). As observed in Fig. 1, the chromatographic
profile of the fractionated Vivinal-GOS is completely
different from those obtained for oligosaccharides de-
rived from lactose or lactulose with Pectinex Ultra SP-L
and Lactozym 3000 L HP G, since the former is a com-
mercial product elaborated under different conditions and
with other enzymes. The trisaccharide 4k-galactosyl-actose
(peak 4) was purified and identified by NMR in the present
work (data not shown). Chemical shifts of 13C NMR
spectra were coincident with those reported in the litera-
ture (Onishi et al. 1995). GOS mixture was composed of
24% 4k-galactosyl-lactose, 15% 6k galactosyl lactose and
61% OOS. Chockchaisawasdee et al. (2005) reported than
GOS fraction of Vivinal-GOS was composed of tri- and
tetrasaccharides with a small amount of oligosaccharides
with a higher DP which possessed a very high percentage
of the 1,4 Gal linkage (55% in the trisaccharide fraction
and 72% in the higher oligosaccharide fraction).
Changes of Bifidobacterium populations in faecal batch
cultures analysed by quantitative real-time PCR
Sugars such as glucose and lactose ingested with foods do
not reach the colon because they are rapidly digested and
adsorbed in the small intestine and, hence they cannot act
as prebiotics. However, glycosidic linkages of lactulose
and trisaccharides derived from lactulose and lactose make
them more resistant to digestion (Tomomatsu, 1994), thus
facilitating their arrival undegraded to the colon. Taking
this consideration in mind, quantitative real-time PCR was
used to evaluate the bifidogenic effect of the four synthe-
sised GOS mixtures compared with the digestible sugars
glucose and lactose as well as to the prebiotics lactulose
and purified Vivinal-GOS (Fig. 2). In general, bifido-
bacteria populations increased through the incubation time,
the highest increase being detected in cultures from indi-
vidual 1 who presented the lowest initial bifidobacterial
values. After 8 and 24 h of incubation all carbohydrate
samples promoted higher increases of bifidobacteria
populations than control cultures, with the exception of
individual 3. In faecal cultures of this individual at 24 h of
incubation the increase of counts in the control was of the
same order as in the presence of the oligosaccharide
samples. These results were indicative of a stimulatory ef-
fect on bifidobacteria growth by external carbon sources
added in individuals 1 and 2 and also in individual 3 after
8 h of incubation. The degree of stimulation varied de-
pending on the carbohydrate source and the individual, as
it was previously stated for other carbohydrates by different
authors. In general, the higher initial level of bifidobacteria
Fig. 1. HPAEC-PAD profiles of oligosaccharides with DP o3 synthesised by Lactozym 3000 L HP G and Pectinex Ultra SP-L from
lactose (GOS-1 and GOS-2, respectively) (A) or lactulose (GOS-3 and GOS-4, respectively) (B) and commercial Vivinal-GOS (C)
obtained after purification with a Bio-Gel P-2 column. Peaks were identified as: (1) 6k galactosyl lactose, (2) 6k galactosyl lactulose,
(3) b-D-Galp–(1p4)-b-D-Fru-(1p1)-b-D-Galp, (4) 4k-galactosyl lactose, OOS: other oligosaccharides.
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resulted in the lower increase of these microorganisms
(Matteuzzi et al. 2004; De Preter et al. 2008; Salazar et al.
2008) and a great variability on stimulatory effect can
be obtained, even when considering a numerous human
population. In the present study, no noticeable differences
were evidenced among the four GOS reaction mixtures
within each individual. However, GOS obtained from
lactose and lactulose promoted, in most cases, slightly
higher count increases than the corresponding di-
saccharides from which they were derived. The bifidogenic
effect of lactulose has been well established (Bouhnik et al.
2004a, b; Macfarlane et al. 2006; Vanhoutte et al. 2006).
It is also known that chemical structures of oligosacchar-
ides may affect their fermentation and prebiotic properties
(Djouzi & Andrieux, 1997; Rycroft et al. 2001). Thus,
generally disaccharides with b(1p2), b(1p4), and b(1p6)
linkages are more suitable as prebiotics than disaccharides
with other different linkages (Sanz et al. 2005) while no
information was reported in relation to b(1p1) glycosidic
linkages. Moreover, in general, carbohydrates with DP=3
showed the highest selectivity towards bifidobacteria
(Kaneko et al. 1994; Kaplan & Hutkins, 2000) which
agreed with our results. In this way our results clearly in-
dicated that GOS mixtures derived from lactose and lac-
tulose which contain in their composition trisaccharides
with high percentage of Gal b(1p6) and/or b(1p1) lin-
kages, exhibited a bifidogenic effect similar or even
slightly higher than their precursor disaccharides and the
commercial oligosaccharide Vivinal-GOS. Further stu-
dies targeting other intestinal microbial groups such as
beneficial bacteria, commensal microorganisms and op-
portunistic pathogens could help to establish the possible
prebiotic role of these new GOS mixtures.
Production of SCFA in faecal batch cultures analysed
by GC-MS
In general, the increase of total SCFA after 8 and 24 h in-
cubation was more pronounced in samples with carbohy-
drates added than in faecal cultures without any external
carbon source, thus indicating that all carbohydrates tested
were able to act as fermentable substrates for the intestinal
microbiota, clearly enhancing the production of SCFA
during incubation. Differences between individuals were
evident with respect to the levels of SCFA finally attained
after incubation, the amount of total SCFA produced fol-
lowing the order individual 1>individual 2>individual 3
(Table 1). Thus, whereas the increase of both propionic
and butyric acids was moderate, a clear rise of acetic acid
occurred during incubation. This increase in acetic acid
was directly related to the increase of bifidobacteria counts
in faecal cultures determined by quantitative real-time
PCR (Table 1 & Fig. 2). As a consequence of this behav-
iour, a clear rise of the acetic to propionic acids ratio was
found during incubation of faecal cultures from individuals
1 and 2. In this respect, several authors stated the en-
hancement of SCFA production by lactulose and other
prebiotics using in vitro and in vivo models (Macfarlane
et al. 2006). Rycroft et al. (2001) highlighted the capacity
of lactulose and GOS to give rise to higher concentrations
of acetic and total SCFA than other oligosaccharides after
short-term incubations.
With respect to the influence of the type of carbo-
hydrate tested on SCFA production no differences were
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Fig. 2. Increase with respect to time 0 of Bifidobacterium counts
measured by quantitative real-time PCR in faecal slurry cultures
from three donors using as carbon sources purified GOS
mixtures (obtained from lactose and lactulose), lactulose,
Vivinal-GOS, lactose, or glucose after 8 (white bars) and 24 h
(grey bars) of incubation. Control does not include carbohydrate
source added. Initial Log CFU/ml Bifidobacterium counts : donor
1=8.28±0.13, donor 2=8.51±0.02, donor 3=8.60±0.05. Error
bars indicate standard deviation.
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Table 1. Concentrations (mM) of the three major SCFA in faecal cultures from three donors using purified GOS mixtures derived from lactose and lactulose, Vivinal-GOS,
lactulose, lactose and glucose as carbon sources
Values are expressed as mean±standard deviation of two independent experiments
Time Sample
Individual 1 Individual 2 Individual 3
Acetic Propionic Butyric Total SCFA Ratio A/P Acetic Propionic Butyric Total SCFA Ratio A/P Acetic Propionic Butyric Total SCFA Ratio A/P
0 h Control 20.43 ± 0.26 5.24 ± 0.40 3.31 ± 01 28.97 ± 0.76 3.91 ± 0.25 30.25 ± 3.18 3.85 ± 0.45 3.96 ± 0.44 38.04 ± 4.06 7.87 ± 0.1 21.12 ± 0.64 2.36 ± 0.11 3.12 ± 0.08 26.60 ± 0.83 8.97 ± 0.15
8 h Control 27.53 ± 1.22 4.04 ± 0.12 4.74 ± 0.015 36.30 ± 1.48 6.81 ± 0.09 22.40 ± 0.48 2.62 ± 0.19 3.06 ± 0.03 28.08 ± 0.64 8.55 ± 0.44 22.34 ± 0.40 2.74 ± 0.07 3.05 ± 0.04 28.13 ± 0.50 8.15 ± 0.04
GOS-1 34.93 ± 1.85 6.16 ± 0.00 5.06 ± 0.16 46.14 ± 2.00 5.67 ± 0.29 24.73 ± 0.03 2.54 ± 0.01 2.94 ± 0.02 30.21 ± 0.05 9.72 ± 0.04 24.38 ± 0.06 2.92 ± 0.02 3.47 ± 0.00 30.77 ± 0.08 8.33 ± 0.03
GOS-2 38.21 ± 2.03 5.59 ± 0.34 5.29 ± 0.11 49.10 ± 2.47 6.83 ± 0.05 37.14 ± 1.00 4.20 ± 0.05 4.04 ± 0.05 45.37 ± 1.09 8.84 ± 0.13 26.37 ± 0.06 3.62 ± 0.00 3.46 ± 0.00 33.46 ± 0.07 7.28 ± 0.00
GOS-3 39.27 ± 0.48 6.20 ± 0.04 5.48 ± 0.02 50.95 ± 0.45 6.33 ± 0.11 36.42 ± 0.24 4.10 ± 0.03 4.00 ± 0.03 44.52 ± 0.18 8.87 ± 0.11 24.20 ± 0.09 2.87 ± 0.01 3.32 ± 0.00 30.40 ± 0.09 8.43 ± 0.00
GOS-4 39.33 ± 0.08 5.54 ± 0.09 5.19 ± 0.02 50.06 ± 0.03 7.09 ± 0.13 37.56 ± 3.27 4.00 ± 0.38 3.80 ± 0.32 45.36 ± 3.96 9.38 ± 0.07 27.73 ± 0.18 3.61 ± 0.01 3.78 ± 0.01 35.13 ± 0.18 7.67 ± 0.07
Vivinal 41.85 ± 0.53 5.60 ± 0.07 5.27 ± 0.06 52.71 ± 0.65 7.47 ± 0.00 36.68 ± 0.73 3.85 ± 0.10 3.88 ± 0.05 44.40 ± 0.88 9.53 ± 0.06 27.98 ± 0.90 3.72 ± 0.27 3.70 ± 0.02 35.40 ± 1.20 7.53 ± 0.30
Lactulose 41.97 ± 1.03 5.16 ± 0.39 5.60 ± 0.07 52.73 ± 1.36 8.15 ± 0.42 32.17 ± 1.29 3.51 ± 0.31 3.36 ± 0.11 39.03 ± 1.71 9.19 ± 0.45 28.84 ± 0.08 3.97 ± 0.02 3.70 ± 0.00 36.52 ± 0.10 7.25 ± 0.01
Lactose 45.73 ± 1.30 6.10 ± 0.16 6.05 ± 0.15 57.87 ± 1.61 7.5 ± 0.013 37.33 ± 0.72 3.73 ± 0.13 3.82 ± 0.08 44.87 ± 0.93 10.01 ± 0.14 28.28 ± 0.94 3.78 ± 0.31 3.61 ± 0.04 35.66 ± 1.29 7.49 ± 0.35
Glucose 33.72 ± 0.11 4.62 ± 0.03 5.42 ± 0.07 43.76 ± 0.20 7.29 ± 0.02 31.16 ± 1.23 3.97 ± 0.71 4.09 ± 0.02 39.42 ± 1.95 8.03 ± 1.15 23.83 ± 2.85 3.81 ± 0.09 3.46 ± 0.02 31.10 ± 2.74 6.27 ± 0.89
24 h Control 44.78 ± 8.67 5.55 ± 1.19 8.33 ± 1.72 58.65 ± 11.58 8.10 ± 0.18 27.13 ± 0.15 4.08 ± 0.0 4.09 ± 0.06 35.30 ± 0.28 6.64 ± 0.10 27.72 ± 0.36 3.44 ± 0.09 4.02 ± 0.06 35.18 ± 0.51 8.06 ± 0.09
GOS-1 76.89 ± 19.88 9.45 ± 2.75 11.27 ± 3.20 97.6 ± 25.83 8.19 ± 0.28 35.04 ± 0.44 3.25 ± 0.13 2.88 ± 0.06 41.16 ± 0.62 10.79 ± 0.29 29.28 ± 0.05 4.39 ± 0.00 4.92 ± 0.06 38.60 ± 0.11 6.66 ± 0.00
GOS-2 100.35 ± 22.13 11.74 ± 2.72 14.65 ± 3.37 126.74 ± 28.22 8.56 ± 0.10 40.22 ± 0.12 4.22 ± 0.01 4.09 ± 0.02 48.52 ± 0.15 9.52 ± 0.00 30.23 ± 0.15 4.91 ± 0.01 4.68 ± 0.03 39.82 ± 0.19 6.15 ± 0.02
GOS-3 111.81 ± 21.49 13.90 ± 3.04 16.22 ± 3.35 141.92 ± 27.88 8.07 ± 0.22 38.97 ± 0.34 4.45 ± 0.40 3.91 ± 0.04 47.32 ± 0.78 8.80 ± 0.72 31.25 ± 0.70 5.54 ± 0.16 5.73 ± 0.13 42.52 ± 1.00 5.64 ± 0.04
GOS-4 118.88 ± 25.22 14.20 ± 3.56 16.82 ± 4.26 149.9 ± 33.04 8.42 ± 0.34 38.27 ± 0.39 3.94 ± 0.28 3.38 ± 0.05 45.58 ± 0.15 9.75 ± 0.79 28.74 ± 0.91 4.67 ± 0.24 5.23 ± 0.02 38.64 ± 1.18 6.16 ± 0.12
Vivinal 120.46 ± 15.54 14.08 ± 2.02 15.50 ± 2.25 150.04 ± 19.8 8.56 ± 0.12 39.63 ± 0.55 3.86 ± 0.00 3.83 ± 0.05 47.32 ± 0.59 10.26 ± 0.13 29.32 ± 0.15 4.87 ± 0.00 4.19 ± 0.03 38.38 ± 0.11 6.01 ± 0.03
Lactulose 74.71 ± 14.65 8.29 ± 1.76 10.38 ± 2.14 93.38 ± 18.54 9.03 ± 0.15 37.19 ± 0.31 3.58 ± 0.02 3.14 ± 0.03 43.91 ± 0.35 10.38 ± 0.03 29.85 ± 0.02 5.14 ± 0.03 4.48 ± 0.01 39.47 ± 0.00 5.81 ± 0.03
Lactose 65.16 ± 6.35 7.97 ± 0.64 9.06 ± 0.89 82.19 ± 7.87 8.16 ± 0.13 37.97 ± 0.06 3.59 ± 0.05 3.77 ± 0.02 45.33 ± 0.01 10.57 ± 0.16 28.67 ± 0.01 4.80 ± 0.02 3.76 ± 0.02 37.23 ± 0.00 5.97 ± 0.01
Glucose 55.72 ± 4.63 8.16 ± 0.52 9.44 ± 1.45 73.31 ± 6.60 6.82 ± 0.13 28.93 ± 1.45 3.49 ± 0.09 3.77 ± 0.02 36.18 ± 1.53 8.28 ± 0.19 30.51 ± 0.12 5.37 ± 0.08 3.89 ± 0.04 39.77 ± 0.08 5.68 ± 0.10
GOS-1: lactose-Lactozym derived oligosaccharides, GOS-2: lactose-Pectinex derived oligosaccharides, GOS-3: lactulose-Lactozym derived oligosaccharides, GOS-4: lactulose-Pectinex derived oligosaccharides
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found among carbohydrates in cultures from individual 3,
who was the lowest SCFA producer. GOS-2, GOS-3, and
GOS-4 mixtures were the best substrates for SCFA pro-
duction, reaching levels of acetic acid and total SCFA
similar to Vivinal-GOS and moderately higher than lac-
tulose, mainly for samples from individual 1 who was the
strongest SCFA producer. In spite of the different origins
and methods employed of obtaining lactulose, Vivinal-
GOS and GOS mixtures, no conclusion can be reached on
a possible relationship between the degree of efficiency
as bifidogenic or fermentable substrates of trisaccharides
identified in the mixtures and their glycosidic linkages and
composition. The moderately higher production of SCFA
in the presence of our GOS fractions with respect to lac-
tulose could be attributed to the synergistic effect of the
different compounds present in the GOS mixtures.
In short, the results presented here allow a preliminary
comparison to be made of the bifidogenic properties of
different types of GOS including new lactulose derived
oligosaccharides. The four purified fractions derived from
lactose and lactulose act as fermentable substrates for in-
testinal bacteria in vitro, enhancing the production of
acetic acid and SCFA and promoting the increase of
Bifidobacterium numbers in human faecal cultures. To the
best of our knowledge, this is the first study of the bifido-
genic effect of the oligosaccharides derived from lactulose.
The GOS derived from lactose and, specially, the novel
oligosaccharides derived from lactulose may represent a
suitable alternative to lactulose for the design of new
functional food ingredients. Further in vivo studies using
animal models and human volunteer trials are necessary in
order to assess the functionality of these GOS mixtures.
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